The most widely used drug for targeting HER2 is trastuzumab, a humanized monoclonal antibody that recognizes an extracellular domain of HER2, ultimately blocking HER2 effects and decreasing cancer cell growth and survival [1]. Here, ERBB2 is linked to cancer.